Chimerix, Inc. (CMRX) News
Filter CMRX News Items
CMRX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CMRX News Highlights
- For CMRX, its 30 day story count is now at 2.
- Over the past 10 days, the trend for CMRX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about CMRX are DEC.
Latest CMRX News From Around the Web
Below are the latest news stories about CHIMERIX INC that investors may wish to consider to help them evaluate CMRX as an investment opportunity.
Positive Signs As Multiple Insiders Buy Chimerix StockUsually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like... |
Chimerix Promotes Michelle LaSpaluto to Chief Financial OfficerProven Leader Brings More Than 25 Years of Financial ExperienceDURHAM, N.C., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced the promotion of Michelle LaSpaluto, Vice President of Corporate Financial Planning and Investor Relations, to Chief Financial Officer effective December 1, 2023. “We are excited to announce this well |
Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)DURHAM, N.C., Nov. 24, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on November 20, 2023, the Compensation Committee of Chimerix’s Board of Directors granted an inducement award to a new employee of non-qualified stock options to purchase 150,000 shares of Chimerix’s common stock. The Compensation Committee of Chimerix’s Board of Directors approved the award as an inducement material to the new employee’s employment agreement in accordance with Nasdaq Listing rule 5635(c |
Chimerix Strengthens Executive Leadership Team with Appointment of Thomas Riga as Chief Operating and Commercial OfficerSeasoned Executive Brings More Than 25 Years of Industry Leadership Experience in Oncology Commercialization and Corporate Business DevelopmentDURHAM, N.C., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced the appointment of Thomas Riga as Chief Operating and Commercial Officer. “We are excited to welcome Tom to the Chimerix |
Chimerix, Inc. (NASDAQ:CMRX) Q3 2023 Earnings Call TranscriptChimerix, Inc. (NASDAQ:CMRX) Q3 2023 Earnings Call Transcript November 2, 2023 Chimerix, Inc. misses on earnings expectations. Reported EPS is $-0.27 EPS, expectations were $-0.22. Operator: Good morning, ladies and gentlemen, and welcome to the Chimerix Third Quarter 2023 Earnings Conference Call. I would now like to introduce you to your host for today’s call, […] |
Chimerix (NASDAQ:CMRX) shareholders have endured a 70% loss from investing in the stock five years agoLong term investing works well, but it doesn't always work for each individual stock. It hits us in the gut when we see... |
Q3 2023 Chimerix Inc Earnings CallQ3 2023 Chimerix Inc Earnings Call |
Chimerix Inc (CMRX) Reports Q3 2023 Financial Results and Operational UpdatesNet Loss of $24.0 Million and Increased R&D Expenses |
Chimerix Reports Third Quarter 2023 Financial Results and Provides Operational Update– Phase 3 ACTION Study Ongoing with 113 Sites Activated Across 12 Countries; Interim Survival and PFS Data on Track to Report in 2025 – – Actively Recruiting ONC206 Dose Escalation Studies; Enrollment on Track to Complete First Half 2024 – – Conference Call at 8:30 a.m. ET Today – DURHAM, N.C., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly disease |
Chimerix to Report Third Quarter 2023 Financial Results and Provide an Operational Update on November 2, 2023DURHAM, N.C., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on Thursday, November 2, 2023 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2023, and to provide a business overview. To access the live conference call, please dia |